NewGenIvf Group (NASDAQ:NIVF) Raised to Hold at Wall Street Zen

NewGenIvf Group (NASDAQ:NIVF) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, NewGenIvf Group has a consensus rating of “Sell”.

NewGenIvf Group Price Performance

NewGenIvf Group stock opened at $0.46 on Friday. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16. NewGenIvf Group has a 1-year low of $0.43 and a 1-year high of $295.17. The firm has a 50-day moving average of $0.94 and a 200-day moving average of $3.32.

NewGenIvf Group shares are set to reverse split before the market opens on Monday, July 6th. The 1-3 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 5th.

NewGenIvf Group (NASDAQ:NIVF) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($287.24) earnings per share for the quarter. The business had revenue of $1.42 million during the quarter. On average, equities analysts expect that NewGenIvf Group will post 4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other NewGenIvf Group news, major shareholder Financial Lp Hrt sold 85,317 shares of NewGenIvf Group stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $0.80, for a total transaction of $68,253.60. Following the sale, the insider directly owned 54,561 shares of the company’s stock, valued at approximately $43,648.80. The trade was a 60.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 31.80% of the company’s stock.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.